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Background. Activation of the renin angiotensin system has
been described in pathologic conditions, including kidney dam-
age. Angiotensin II (Ang II) acts through two receptors, AT1
and AT2. Most of the known actions of Ang II, including vaso-
constriction and fibrosis, are due to AT1 activation. Recent
data suggest that AT2 participates in the regulation of cell
growth and renal inflammatory infiltration. Therefore, we inves-
tigated the renal expression of AT2 receptors in several models
of renal injury.
Methods. Investigations were done in the following experi-
mental models of kidney damage: systemic infusion of Ang II
(inflammation), folic acid nephropathy (tubular cell death),
and protein overload proteinuria. AT2 expression was deter-
mined by immunohistochemistry (protein) and reverse tran-
scription-polymerase chain reaction (RT-PCR) (gene).
Results. In control animals, low levels of renal expression of
AT2 were found. Ang II infusion resulted in an up-regulation
of AT2 in tubular cells and de novo AT2 expression in glomeruli
and vessels, associated with the presence of inflammatory cells.
Acute tubular injury induced by folic acid was characterized by
AT2 overexpression and apoptosis in tubular cells. Protein over-
load caused heavy proteinuria and tubular AT2 up-regulation.
Conclusion. AT2 is re-expressed in pathologic conditions of
kidney damage, such as inflammation, apoptosis, and protein-
uria, suggesting a potential role of this receptor during renal
injury.
Activation of the local renin angiotensin system (RAS)
has been described in pathologic conditions, including
kidney damage. Angiotensin II (Ang II), the main ef-
fector peptide of the RAS, is a pleiotropic cytokine in-
volved in the regulation of cell growth, fibrosis, and in-
flammatory response [1, 2]. Ang II binds to two main
receptors: AT1 and AT2. Both receptor subtypes have
been cloned and pharmacologically characterized. There
are other potential Ang receptors, the AT3 and AT4, not
yet included in a definitive classification [3, 4]. Most of
the physiologic actions of Ang II, such as the regulation
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of blood pressure and water-electrolyte balance, are
mediated by AT1. This receptor is widely distributed
throughout the cardiovascular, renal, endocrine, and ner-
vous system in humans. AT1 receptor is also involved
in growth-promoting effects, fibrotic, thrombotic, and
inflammatory processes through activation of various sig-
nal-transduction pathways, including calcium mobiliza-
tion, activation of protein kinases, and production of
reactive oxidant species [3, 4].
The biological functions and the signaling pathway of
AT2 are not completely known. AT2 induces apoptosis
and cell growth inhibition, vasodilatation, and regulates
diuresis/natriuresis, renal nitric oxide (NO) production,
and glomerular monocyte infiltration [3–6]. AT2 signal-
ing activates phosphatases and production of ceramides,
arachidonate, and kinin/NO/cGMP [3, 4]. The AT2 re-
ceptor is ubiquitously expressed in human fetal mesen-
chymal tissues, but its expression declines after birth [7].
In adults, AT2 receptor expression is detectable in the
pancreas, heart, kidney, adrenals, brain, and vasculature
[3, 4, 8]. AT2 is re-expressed in pathologic situations
involving tissue remodeling or inflammation, such as
neointima formation, heart failure, and wound healing
[3, 9–11]. However, the role of AT2 receptors in renal
disease remains to be defined.
Many investigators have demonstrated the presence
of AT1 in the adult kidney and in cultured renal cells.
However, there are still some controversial data about
renal AT2 [1, 3, 4, 8]. Our aim was to investigate the
renal expression of AT2 in experimental models of renal
injury of different etiology, such as infusion of Ang II
[6, 12], acute renal injury by folic acid, which is associated
to apoptosis of tubular cells [13], and a model of heavy
proteinuria caused by protein overload [14, 15].
METHODS
Experimental design
Angiotensin infusion was done during 3 days with os-
motic subcutaneous minipumps (Alza Corp., Cupertino,
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CA, USA). Studies were done in Wistar rats (Ang II at
dose of 50 ng/kg/min), as previously described [6, 12],
and in mice (1000 ng/kg/min). In these studies we used
saline-infused animals as control (N  8 each). Studies
in mice were done in the following experimental groups:
(1) AT1a receptor knockout male mice that were gener-
ated with a germ-line chimera derived from TT2 embry-
onic stem (ES) cells with a targeted mutation of the AT1A
gene (Tanabe Seiyaku Corp, Osaka, Japan) [16]; and (2)
wild-type (WT; C57BL/6). AT1 knockout mice were back-
crossed for more than 6 generations with C57BL/6 mice.
C57BL/6 and Balb/c mice were purchased from Harlan
Interfauna Ibe´rica, S.A. (Barcelona, Spain). Eight animals
from each group were studied.
Folic acid-induced nephropathy. Acute tubular injury
was induced by a single injection of folic acid (250 mg/kg)
in Balb/c mice as described [13], and animals were stud-
ied after 24 hours. Saline injection was used as control
in all models.
Overload proteinuria was induced in Sprague-Dawley
rats by daily intraperitoneal injections of 2 g bovine se-
rum albumin (BSA) for 7 and 14 days [14].
At the end of the study period, animals were sacrificed
under pentobarbital anesthesia and kidneys were re-
moved and processed in liquid nitrogen for RNA studies
or treated to obtain paraffin sections for histology and
immunohistochemistry.
AT2 protein expression by immunohistochemistry
Paraffin-embedded renal tissue sections (4 m) were
mounted on poly-l-lysine-coated slides. The slides were
deparaffinized with xylene and graded concentrations of
ethanol and then rehydrated. The endogenous peroxi-
dase was blocked by incubating in 3% H2O2/methanol
(1:1) at 25C for 30 minutes. The slides were treated with
0.01% trypsin in HCl for 15 minutes at 37C. To reduce
nonspecific background staining, slides were incubated
in buffer A [phosphate-buffered saline (PBS) with 2%
horse serum, 4% BSA, and 0.1% trypsin] for 1 hour at
room temperature, and incubated overnight at 4C with
a specific goat anti-AT2 antibody (Santa Cruz, #sc-9040;
tested by Western blot) [17] and a rabbit anti-AT1 (N-10)
receptor antibody (Santa Cruz, #sc-1173). After washing
with PBS, the sections were incubated with secondary
anti-immunoglobulin G (IgG) biotinylated-conjugated
antibody diluted 1:200 without horse serum for 30 min-
utes. Detection was done by incubation with ABC com-
plex (Dako Corp., Carpinteria, CA, USA) for 30 min-
utes, after 0.05% 3,3-diaminobenzidine (Dako Corp.)
in 0.3% H2O2 for 5 minutes. The sections were counter-
stained with Mayer’s hematoxylin and mounted in Pertex
(Medite, Burgdorf, Germany). In each experiment, nega-
tive control without the primary antibody, or using an
unrelated antibody, were included to check for nonspe-
cific staining.
In overload nephropathy, the immunolabeled surface
area was evaluated by quantitative image analysis using
a KZ 300 Imaging System 3.0 (Zeiss, Mu¨nchen-Hallberg-
moos, Germany), and the degree of staining was calcu-
lated by the ratio of suitable binary threshold images
and the total field area integrating the intensity of the
staining in the specific areas. For each sample, the mean
staining was obtained by analysis of 20 different fields
(at 10), excluding glomeruli and vessels. Quantification
was done twice, independently. The staining score was
expressed as density/mm2.
Determination of mRNA expression of AT2
Total RNA was obtained from the renal cortex by
homogenization and isolation with Trizol (Invitrogen,
Carlsbad, CA, USA). AT2 mRNA expression was ana-
lyzed by reverse transcription-polymerase chain reac-
tion (RT-PCR), with specific primers 5-TGGAGTT
GCTGCAGTTCAAT-3 (sense) and 5-TCCCGGAA
ATAAGTTGG-3 (antisense), yielding a 568 bp prod-
uct. PCR amplification (1 minute at 94, 1 minute at 58,
and 2 minutes at 68) was linear up to 35 cycles, and data
corresponding to cycle 35 were used for calculations.
Control experiments were done with RNA samples, but
without avian myeloblastosis virus (AMV) reverse tran-
scriptase.
RESULTS
Renal AT2 expression is up-regulated in different
experimental models of renal injury
Protein levels of AT2 in the kidney were evaluated by
immunohistochemistry. In renal sections of control rats
and mice there was positive immunostaining for AT2
located in tubuloepithelial cells, while no staining was
observed in glomeruli (Figs. 1 and 2).
In Ang II–infused rats (Fig. 1), increased staining for
AT2 was observed in tubuloepithelial cells. In addition,
induction of AT2 was found in glomeruli, mainly in the
mesangial area and vascular smooth muscle cells (VSMC)
of renal vessels. Infusion of Ang II for 3 days also caused
infiltration of inflammatory cells in glomerular and tubu-
lointerstial areas [6].
In Ang II–infused mice (Fig. 2), AT2 over-expression
was also observed, mainly in tubular cells. In contrast,
there was no induction in glomeruli. In this model we
have described focal interstitial infiltration, mainly of
macrophages, but inflammatory cells were absent in the
glomeruli [12]. In AT1 knockout mice, AT2 expression
was also elevated in some tubuli by Ang II infusion
(Fig. 2). By RT-PCR we analyzed AT2 gene levels in the
mice model. In control kidneys a band corresponding to
the AT2 mRNA was observed. In Ang II–infused mice
AT2 mRNA was up-regulated, both in WT and AT1
knockout mice (Fig. 3). These data suggest an association
between the presence of infiltrating cells and renal AT2
over-expression.
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Fig. 1. Systemic infusion of angiotensin II (Ang II) into rats up-regu-
lates renal AT2 expression. Immunohistochemistry was done as de-
scribed in Methods. In control rats, AT2 is present in low levels in some
tubular cells. In Ang II–infused rats for 3 days AT2 is over-expressed
in tubular cells and appeared in glomeruli. Negative control samples
were incubated in the absence of primary antibody.
Fig. 2. Systemic infusion of angiotensin II (Ang II) into mice up-regu-
lates tubular AT2 expression. In Ang II–infused mice AT2 expression
was elevated in tubular cells compared to control mice. Similar results
were found in AT1 knockout mice.
In acute renal injury induced by folic acid in mice,
renal AT2 mRNA over-expression was observed (Fig. 3).
AT2 staining was also increased, mainly in tubular cells
(Fig. 4), and correlated with elevated levels of apoptotic
proteins [13].
In rats with overload proteinuria, AT1 was distributed
in the cortex and medulla, mainly in distal tubules and
to a lesser extent in proximal tubuli and blood vessels.
AT2 staining was observed more intensely in the cortex
than in the medulla, and its distribution was stronger in
distal tubules and blood vessels, reaching significant dif-
ferences both after the 7th and 14th injection (Fig. 5).
Fig. 3. Analysis of AT2 mRNA expression by reverse transcription-
polymerase chain reaction (RT-PCR) in murine models of renal dam-
age. Total RNA from renal cortex of control mice expressed AT2
mRNA. In both models—infusion of (A ) Ang II and injection of (B )
folic acid—AT2 mRNA expression was increased compared to control
animals.
Fig. 4. Angiotensin II receptor type 2 (AT2) is up-regulated in folic
acid–induced renal injury. In control Balb-c mice, a weak staining for
AT2 in tubular cells was observed. Injection of folic acid up-regulated
tubular AT2 expression.
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Fig. 5. (A ) Immunohistochemical expression
of AT1 and AT2 receptors in control animals
and rats with overload nephropathy. (B ) Im-
age analyzer quantification of immunohisto-
chemical expression of AT1 and AT2. White
bars represent AT1 and black bars represent
AT2. P  0.05 compared with AT1.
These animals presented heavy proteinuria, elevated
blood pressure, severe tubulointerstitial inflammation,
and activation of the fibrogenesis process [14].
DISCUSSION
Our data show that AT2 is up-regulated during renal
injury independently of the initial cause of damage, and is
associated with different features, such as inflammation,
proteinuria, and apoptosis. These data, together with the
information provided by AT2 blockers and AT2 knockout
mice [3, 4, 18, 19], support an important role for AT2 in
the pathophysiology of the kidney.
Systemic infusion of Ang II for 3 days into rats in-
creases renal AT2 expression in tubular cells. The AT2
up-regulation occurs simultaneously with the presence of
inflammatory cells in glomeruli and in tubulointerstitial
areas in a focal manner [5, 6], and the elevation of pro-
inflammatory parameters in the kidney, including nuclear
factor kappa B (NF-B) activation and production of
chemokines and cytokines [5, 6, 20]. Interestingly, AT2
blockade diminished renal inflammatory cell infiltration,
NF-B activation, and over-expression of related genes
caused by Ang II infusion [5, 6, 12]. All these data show
that a potential mechanism involved in Ang II–induced
renal inflammation is the AT2/NF-B pathway, exten-
sively discussed in another work in this supplement [12].
The potential clinical implications of these findings need
to be addressed in human diseases.
Persistent proteinuria contributes to tubulointersti-
tial damage in human and experimental renal diseases
[21, 22]. However, the mechanisms by which proteinuria
could cause interstitial inflammation and fibrosis are still
not fully understood. The experimental model of protein
overload in rats is characterized by heavy and sustained
proteinuria. In this model, we have observed up-regula-
tion of AT2 in tubular cells. We have previously shown
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that persistent proteinuria elicited renal RAS activation,
shown by elevated angiotensin-coverting enzyme (ACE)
in tubular epithelial cells [15]. One potential mechanism
by which persistent proteinuria may participate in the
progression of renal disease is through the Ang II/NF-B
pathway. In this sense, rats and mice with protein over-
load nephropathy present elevated renal NF-B activity
and over-expression of chemokines, which were prevented
by ACE inhibition treatment [14, 23]. In AT1 knockout
mice with overload nephropathy, proteinuria, tumor ne-
crosis factor- (TNF-) mRNA expression, and NF-B
activity was similar to those found in WT. Moreover,
interstitial infiltration was higher in AT1 knockout than
in WT mice [14]. These data suggest that heavy protein-
uria may cause NF-B activation and related proinflam-
matory responses independently of AT1, further support-
ing the idea that the AT2/NF-B pathway participates in
renal inflammatory processes, at least in that condition.
In contrast, AT1 knockout mice with overload nephropa-
thy had significantly less activator protein-1 (AP-1) acti-
vation and mRNA expression of transforming growth
factor-	 (TGF-	) and extracellular matrix proteins [14],
showing that AT1 regulates fibrosis, as observed in response
to AT1 blockade in different models of renal injury [1].
Folic acid nephropathy is a classic model of acute
tubular injury. In mice, injection of folic acid increased
renal AT2 gene and protein, mainly in tubular cells. Folic
acid caused apoptosis and changes in the expression of
apoptosis regulatory genes (Bcl2) in tubular epithelium
[13]. This resulted in a decreased Bcl2/Bax ratio that
favored cell death. In cultured cells, AT2 stimulation
caused apoptosis via caspase activation and ceramide
production [4], and induced dephosphorylation of Bcl-2
[24]. In cultured tubular cells, serum deprivation, TNF,
and Ang II stimulation caused apoptosis [13, 25]. Al-
though there are no studies in cultured tubular cells,
serum deprivation up-regulated AT2 in mesangial cells
and VSMC [26, 27], showing that factors involved in
apoptosis could also be responsible for the tubular AT2
over-expression found in folic acid nephropathy. AT2
may also be involved in apoptosis through the NF-B
pathway. In most cell types, NF-B mediates cell survival
signals, protecting cells from apoptosis, but in other con-
ditions it may also induce apoptosis [28]. Our data clearly
show that during acute renal injury, there was an AT2
up-regulation associated with apoptosis of tubular cells,
suggesting that a potential relationship merits further
investigation.
In other models of renal damage, AT2 up-regulation
has previously been described. In rats with immune com-
plex glomerulonephritis, which presented an activation
of the renal RAS [29], a strong glomerular staining with
the anti-AT2 antibody was noted [6]. In the adult rat, so-
dium depletion was associated with increased renal AT2
[8], suggesting that homeostatic adaptations to changes
in salt and water balance, which may trigger activation
of the RAS, may result in increased expression of the
AT2. Up-regulation of AT2 has also been found in other
pathologic conditions, including vascular damage and
wound healing [3, 9–11]. Future studies are needed to
determine the expression levels of AT2 in human kid-
ney diseases.
The mechanisms of the regulation of AT2 mRNA ex-
pression in renal cells are poorly understood. However,
mouse fibroblast R3T3 cells have been extensively stud-
ied. In these cells, interleukin-1	 (IL-1	), insulin, and
Ang II up-regulate AT2 expression, while serum (10%),
fibroblast growth factor, phorbol ester, and lysophos-
phatidic acid reduced it [30, 31]. The competitive binding
of interferon regulatory factor (IRF)-1 and IRF-2 tran-
scriptionally regulates AT2 expression. IRF-1 increases
growth-dependent AT2 expression, whereas IRF-2 inhib-
its it [32]. In these cells, up-regulation of IRF-1 and AT2
exert proapoptotic effects [33]. In the promoter region
of the mouse AT2 gene there are potential cis DNA ele-
ments that respond to IL-1	 (CCAAT enhancer binding
protein site), insulin (insulin response sequence of phos-
pho(enol)pyruvate carboxykinase gene), and phorbol es-
ter (AP-1 site). In cultured mesangial cells and VSMC,
prolonged serum depletion induced AT2 mRNA expres-
sion. This effect was only found in cells from Wistar-
Kyoto rats, but not from spontaneously hypertensive rats
(SHR) [26, 27]. In VSMC, insulin-like growth factor up-
regulates AT2 [34], and in rat neonatal myocytes, protein
kinase C activators, such as Ang II down-regulated AT2
mRNA level [35]. These data show that AT2 expression
is regulated by many stimuli, in positive and negative
directions, which vary in the different cell types.
The role of AT2 in cell growth is not completely de-
fined. In mesangial cells the stage of growth modulates
AT2 expression, therefore, in confluent cells AT2 expres-
sion was greatly increased [21]. In vitro studies have
demonstrated that AT2 stimulation inhibits the growth
of various cell types, including mesangial, VSMC, endo-
thelial cells, cardiomyocytes, and cardiac fibroblasts [3, 4].
However, the results of in vivo studies in the cardiovascu-
lar system are controversial [11]. Some experimental
studies, using in vivo transfer of the AT2 gene and AT2
knockout mice showed that AT2 could inhibit VSMC
growth in vivo. AT1 antagonist administers to AT2 knock-
out mice decreases vascular lesion to a lesser extent than
in WT, supporting the hypothesis of AT2 stimulation
during AT1 blockade [36]. However, other works show
opposite results, implicating the AT2 receptors in cardiac
hypertrophy and fibrosis [37]. In AT2 knockout mice
with Ang II–induced hypertension, left ventricular hy-
pertrophy and interstitial collagen type I was absent [38].
These contrasting results emphasize that the role of AT2
in human diseases needs to be investigated.
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CONCLUSION
Our data show that after diverse initiating insults, AT2
over-expression is a common feature of kidney injury.
Future research on the role of AT2 in human renal dis-
eases is necessary, particularly in view of the emerg-
ing importance of the RAS and its inhibition in clinical
practice.
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